972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma
Kevin J. Harrington, William N. William, Anuradha Khilnani, Alain P. Algazi
Topics & Concepts
MedicinePembrolizumabOncologyHead and neckHead and neck squamous-cell carcinomaInternal medicinePhases of clinical researchHead and neck cancerChemotherapyRadiation therapyImmunotherapySurgeryCancerRadiopharmaceutical Chemistry and ApplicationsHead and Neck Cancer StudiesCancer Immunotherapy and Biomarkers